why choose us

First received: November 16, 2022

Clinical Trial: Expanded Access Program for Magrolimab

Study Type: Expanded Access


Brief Summary: The primary objective of this study is to provide rapid access to magrolimab free-of-cost material, to treat patients in the United States suffering from relapsed or refractory higher-risk myelodysplastic syndrome (MDS) or relapsed or refractory acute myeloid leukemia (AML).

Read more